Sbir topic 401 phase II
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91023C00043
- Awardee
-
Malcova Inc. UEI GSB6L7B1FB13
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,998,128
Award facts
- Opportunity
-
- BAA75N91022R00027 Solicitation number
- Contract value 100% obligated
- $1,998,128.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Newark, CA 94560, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
Malcova Inc., a small business specializing in advanced medical imaging technologies for breast cancer detection, was awarded a $2.0 million firm fixed price contract by the National Cancer Institute under the Small Business Innovation Research (SBIR) Program Phase II on September 18, 2023. This 27-month contract, set aside exclusively for small businesses, extends through September 17, 2025, and focuses on developing patient-derived anthropomorphic phantoms for automated objective assessment of breast imaging systems. The work will be performed at Malcova Inc.'s facility in Newark, California, with the contract classified as a definitive contract with firm fixed price terms.
The SBIR Program Phase II award represents a significant investment in advancing Malcova Inc.'s research and development efforts to enhance breast imaging technology evaluation capabilities. The specialized phantoms being developed under this contract will enable objective, automated assessment methodologies for breast imaging systems, supporting the National Cancer Institute's broader mission to improve cancer screening and detection. This award builds upon Malcova Inc.'s existing federal funding portfolio, which includes NSF and NCI grants focused on developing innovative breast imaging solutions, including novel spectral computed tomography and narrow-beam CT technologies designed to improve cancer detection in women with dense breast tissue.
Quick answers
Who was awarded contract 75N91023C00043?
75N91023C00043 was awarded to Malcova Inc. by National Cancer Institute (National Institutes of Health) on September 18, 2023.
How much is contract 75N91023C00043 worth?
The government has obligated $1,998,128 on 75N91023C00043.
Was contract 75N91023C00043 competed?
The extent of competition for 75N91023C00043 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award